Evidence map›Paper›PMID 27186071›Full record

ArticleMolecular vision2016

Evaluation of treatment for dry eye with 2-hydroxyestradiol using a dry eye rat model.

Akihiro Higuchi, Erina Oonishi, Tetsuya Kawakita, Kazuo Tsubota

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Potential New Target for Dry Eye Disease-Oxidative Stress.Antioxidants (Basel, Switzerland) · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Akihiro HiguchiShinanomachi Research Park 6N9, Center for Integrated Medical Research, Keio University, School of Medicine, Tokyo, Japan; Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
Erina OonishiShinanomachi Research Park 6N9, Center for Integrated Medical Research, Keio University, School of Medicine, Tokyo, Japan; Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
Tetsuya KawakitaDepartment of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
Kazuo TsubotaDepartment of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
Keio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose2-hydroxy estradiol (2-OHE2) is a catechol derivative of 17β -Estradiol (E2) and it is synthesized from E2 catalyzed by cytochrome P4501A1. Previous studies reported that 2-OHE2 is a physiologic antioxidant in lipoproteins, liver microsomes, and the brain. Catechol derivatives show an anti-inflammatory effect through the inhibition of prostaglandin endoperoxide synthase (PGS) activity. Corneal erosion caused by dry eye is related to an increase in oxidative stress and inflammation in ocular surface cells. We investigated the therapeutic effects of 2-OHE2 on corneal damage caused by dry eye.

methodsSteroidal radical scavenging activity was confirmed through the electron spin resonance (ESR) method. PGS activity was measured using the COX Fluorescent Activity Assay Kit. To evaluate the effect of 2-OHE2 on the treatment for dry eye, 2-OHE2 was applied as an eye drop experiment using dry eye model rats.

results2-OHE2 scavenged tyrosyl radical and possibly suppressed oxidative stress in corneal epithelial cells. In addition, 2-OHE2 inhibited PGS activity, and 2-OHE2 is probably a competitive inhibitor of PGS. Corneal PGS activity was upregulated in the dry eye group. Therefore, 2-OHE2 eye drops improved corneal erosion in dry eye model rats.

conclusions2-OHE2 is a candidate for the treatment of dry eye through the suppression of inflammation and oxidative stress in the cornea.

Indexed as

Disease Models, AnimalAnimalsCell LineCorneal DiseasesCyclooxygenase 2Drug Evaluation, PreclinicalDry Eye SyndromesElectron Spin Resonance SpectroscopyEpithelium, CornealEstradiolFree Radical ScavengersHeme Oxygenase (Decyclizing)Interleukin-6MaleMatrix Metalloproteinase 9Ophthalmic Solutions2-hydroxyestradiolCyclooxygenase 2EstradiolFree Radical ScavengersHeme Oxygenase (Decyclizing)Hmox1 protein, ratInterleukin-6Matrix Metalloproteinase 9Mmp9 protein, ratOphthalmic SolutionsProstaglandin-Endoperoxide SynthasesPtgs2 protein, ratRNA, MessengerTumor Necrosis Factor-alpha

Identifiers

PMID27186071
PMCPMC4859160
OpenAlexW2346242033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.